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Background: Stress urinary incontinence (SUI) is common after radical prostatectomy
and likely to persist despite conservative treatment. The sling is an emerging operation
for persistent SUI, but randomised controlled trial (RCT) comparison with the estab-
lished artificial urinary sphincter (AUS) is lacking.
Objective: To compare the outcomes of surgery in men with bothersome urodynamic
SUI after prostate surgery.
Design, setting, and participants: A noninferiority RCT was conducted among men with
bothersome urodynamic SUI from 27 UK centres. Blinding was not possible due the
surgeries.
Intervention: Participants were randomly assigned (1:1) to the male transobturator
sling (n = 190) or the AUS (n = 190) group.
Outcome measurements and statistical analysis: The primary outcome was patient-
reported SUI 12 mo after randomisation, collected from postal questionnaire using a
composite outcome from two items in validated International Consultation on Inconti-
nence Questionnaire-Urinary Incontinence Short Form questionnaire (ICIQ-UI SF). Non-
inferiority margin was 15%, thought to be of acceptable lower effectiveness, in return for
reduced adverse events (AEs) and easier operation, for the sling. Secondary outcomes
were operative and postoperative details, patient-reported measures, and AEs, up to
12 mo after surgery.
Results and limitations: A total of 380 participants were included. At 12 mo after
randomisation, incontinence rates were 134/154 (87.0%) for male sling versus 133/
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= 0.003), showing noninferiority. Incontinence symptoms (ICIQ-UI SF) reduced from
scores of 16.1 and 16.4 at baseline to 8.7 and 7.5 for male sling and AUS, respectively
(mean difference 1.4 [95% CI 0.2–2.6], p = 0.02). Serious AEs (SAEs) were few: n = 6 and
n = 13 for male sling and AUS (one man had three SAEs), respectively. Quality of life
scores improved, and satisfaction was high in both groups. All other secondary outcomes
that show statistically significant differences favour the AUS.
Conclusions: Using a strict definition, urinary incontinence rates remained high, with no
evidence of difference between male sling and AUS. Symptoms and quality of life
improved significantly in both groups, and men were generally satisfied with both
procedures. Overall, secondary and post hoc analyses were in favour of AUS.
Patient summary: Urinary incontinence after prostatectomy has considerable effect on
men’s quality of life. MASTER shows that if surgery is needed, both surgical options result
in fewer symptoms and high satisfaction, despite most men not being completely dry.
However, most other results indicate that men having an artificial urinary sphincter have
better outcomes than those who have a sling.
© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Stress urinary incontinence (SUI) is a common symptom in
men after radical prostatectomy and can be difficult to
improve. Even after physiotherapy, 75% of men who
remained incontinent after 6 wk have some leakage even
12 mo after their prostate surgery [1]. Implantation of the
artificial urinary sphincter (AUS) is the recommended
surgical procedure for men who have had insufficient
benefit from conservative treatments, and still have
troublesome SUI >12 mo after surgery [1,2]. As the AUS
is relatively expensive, requires specialist surgical skill to
implant, and may require revisions over time, other surgical
methods have been tested. These have not been evaluated in
adequately powered randomised controlled trials (RCTs), as
concluded in the 2011 Cochrane review and National
Institute for Health and Clinical Excellence (NICE) guidance
(CG97), with no new RCTs since these were published
[1,3,4]. Male slings of many varieties have also been
reported in case series over the past decade, and have
been increasingly used for the treatment of postprosta-
tectomy incontinence (PPI), again without high-level
evidence [1,2,5]. The current NICE guidance (CG97), last
updated in 2015 (accessed August 2019), remains un-
changed [1]. The 2017 International Consultation on
Incontinence (ICI) [2] states the following: the AUS is
“the preferred treatment”; “male slings are an acceptable
surgical approach with several years’ follow-up supporting
their safety and efficacy in men with mild to moderate
degrees of PPI”; and “injectable agents, even with repeated
application, have a low success rate”. The 2018 European
Association of Urology (EAU) guidelines are similar
[5]. Hence, current authoritative recommendations support
the need for an RCT such as MASTER, making its findings
relevant to current clinical practice.
Owing to these uncertainties, the aim of MASTER was to
compare the AUS and passive suburethral synthetic slings
(“male slings”) in an RCT. At the planning stage of MASTER,
there were little reasonable data on compressive slings
(LE4 evidence), and compressive slings appeared to have
higher complication and reoperation rates. Furthermore, thecompressive sling technology was changing, and operative
procedures appeared to have little standardisation. For these
reasons, we decided that MASTER should reflect this and
current practice, which was that the male slings used
predominantly by the MASTER surgeons were passive in type
(advanced). This decision is still supported by the current
2020 EAU guidelines, which recommend offering fixed slings,
but add that “there is limited evidence that adjustable male
slings can cure or improve SUI in men”, “there is limited
evidence that early explantation rates are high”, and “there is
no evidence that adjustability offers additional benefit over
other types of sling”, each being LE3 evidence [6].
2. Patients and methods
The full methodology, including a flowchart, is described in the
published protocol (https://trialsjournal.biomedcentral.com/articles/
10.1186/s13063-018-2501-2) [7]. This report focusses on the 12-mo
primary and main secondary outcomes. Future papers will report the 24-
mo outcomes, and qualitative and economic outcomes.
2.1. Patients
Men who had decided, in discussion with their urologist, to have
surgery for persistent bothersome SUI resulting from prostate surgery
and were willing to be randomised between male sling and AUS were
included in the MASTER RCT (International Randomised Controlled
Trial Registry, ISRCTN49212975; registered on 22 July 2013). In line
with current practice, men were not considered unless they had failed
conservative treatment including pelvic floor exercises, stress inconti-
nence was confirmed on urodynamics (UDS; urodynamic stress
incontinence [USI]), and 12 mo had elapsed since their prostate
surgery [7].
Men were excluded if they had had previous male sling or AUS
surgery, had unresolved bladder neck contracture or urethral stricture
after prostate surgery, had insufficient manual dexterity to operate the
AUS device, or were unable to give informed consent or complete trial
documentation [7].
2.2. Study design and ethical approval
MASTER was a multicentre, randomised, controlled, noninferiority trial
of surgery for men with USI after prostate surgery. The primary outcome
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at 12 mo after randomisation. Our reason for this approach was that if a
male sling is inferior in the short term, then male slings will highly likely
not be introduced throughout the NHS, irrespective of longer-term costs
and consequences.
Participants were recruited from 27 UK urological centres.
Ethical approval was received by the National Research Ethics
Service (NRES) South West – Frenchay Research Ethics Committee:
Reference Number 13/SW/0132, and all men gave written informed
consent.
2.3. Randomisation and masking
Randomisation was carried out as close to the time of surgery as
practical. Patients were randomised using a probabilistic algorithm to
either a male sling or an AUS in a 1:1 ratio, minimising for type of
prostate surgery (radical prostatectomy or transurethral resection of the
prostate [TURP]), previous prostate radiotherapy (yes or no), and centre,
using a remote automated computer-allocated randomisation system
hosted at the Centre for Healthcare Randomised Trials (CHaRT) in
Aberdeen, UK. Participants could not be blinded to their allocated
procedure since the AUS requires the patient to operate the device, while
the male sling does not.
2.4. Procedures
All surgeons were competent at AUS implantation. Surgeons who were
relatively inexperienced in male sling implantation were mentored until
deemed competent by principal investigators who were experienced in
male sling surgery. Detailed guidance on surgical technique was written,
for example, “balloon placed in extraperitoneal pocket”; the protocol was
endorsed by all participating centres [7].
2.5. Clinical outcome and patient-reported outcome measures
The primary clinical outcome was any self-reported urinary inconti-
nence (UI) at 12 mo after randomisation, a composite outcome derived
from responses indicating any loss of urine to either of the two
questions: “how often do you leak urine?” and “how much urine do you
leak?” (from the validated International Consultation on Incontinence
Questionnaire-Urinary Incontinence Short Form questionnaire [ICIQ-UI
SF]) [8].
The data monitoring committee suggested using a less strict
definition of the primary outcome; this included “less than once a
week” and “a small amount” in the definitions of success and was
analysed in the same way. This was taken to define only more severe
cases as being incontinent at 12 mo, that is, those that leaked one or more
times a week.
The secondary clinical outcome and patient-reported outcome
measures (PROMs) were operative and postoperative details, adverse
events (AEs), readmissions, UI (ICIQ-UI SF score [8]) and incontinence
pad usage, 24-h pad test (weight of urine lost), and lower urinary tract
symptoms (ICIQ-Male Lower Urinary Tract Symptoms [ICIQ-MLUTS])
[9]. Quality of life outcome measures included interference on everyday
life (ICIQ-UI SF [8]), sexual matters (ICIQ-MLUTSsex [10]), general health
measures (SF12 [11] and EQ-5D [12]), and satisfaction with treatment
(ICIQ-satisfaction [13]). Men completed postal questionnaires and
urinary diaries at 6 mo after surgery and 12 mo after randomisation,
and had a clinical review and a 24-h pad test at 12 mo after surgery. Men
who reported that they were dry at 12 mo did not need to complete the
24-h pad test if they did not wish to do so. Similarly, no 24-h pad test was
available for those who did not attend clinic for their 12-mo review (in
these cases, the clinic review occurred by telephone or from review ofpatient notes). Hence, quantification of incontinence severity in both
cases was self-reported, categorised into small/moderate/large and
semiobjective, using 24-h pad tests.
2.6. Sample size
Limited evidence from case series suggested that 20% of men would still
be incontinent 12 mo after AUS. Assuming no difference between the
arms, we required outcome data on 310 participants for 90% power to
show that male slings were noninferior to AUS by a margin of 15%. The
figure of 15% was a clinical decision on what noninferiority margin would
be considered acceptable and was supported by the qualitative inter-
views with men (to be reported later). We allowed for a 15% loss to
follow-up, inflating to 360 participants in total (180 per group) [7].
2.7. Statistical analysis
An analysis was done (by D.C.) based on randomised allocation (intention
to treat), used data collected in the 12-mo follow-up questionnaire and
the 12-mo clinic appointment. We used a generalised linear model with
previous prostate radiotherapy and pad test weight at baseline and a
random effect (intercept) for centre to analyse the primary outcome. We
used the lower limit of the two-sided 95% confidence around the
difference between groups to infer noninferiority between male slings
and AUS, which is equivalent to a 2.5% one-sided type 1 error rate. We
calculated a p value for observing the difference under the null
hypothesis of inferiority.
EQ-5D [12] and ICIQ-UI SF [8] scores were analysed using a mixed-
effect repeated-measure model on all available 6- and 12-mo data,
adjusting for baseline outcome measure and design covariates (as for the
primary outcome). Effect sizes are presented as the difference between
groups with 95% confidence interval (CI) and a superiority p value.
Differences between complication rates or readmission rates are
presented as the risk difference and CI.
Pad use is analysed as a count variable with a negative binomial
model adjusting for baseline pad use, previous radiotherapy, and
clustering on centre. The frequency and amount of urine leakage are
analysed using ordered logistic regression with the same design
covariates as the primary outcome. These analyses were added to aid
in the interpretation of the primary outcome.
A subgroup analysis of the primary outcome by baseline pad weight
was performed as outlined in the statistical analysis plan. The subgroup




Between 29 January 2014 and 28 December 2017, 380 men
were randomised to receive a male sling or an AUS (190 in each
group; Fig. 1). The groups were similar at baseline (Table 1).
3.2. Primary outcome
There were 134/154 (87.0%) incontinent men in the male
sling group versus 133/158 (84.2%) in the AUS group, 12 mo
after randomisation (difference –3.6% [95% CI –11.6 to 4.6],
pNI = 0.003; Table 2), confirming noninferiority. The “less
strict” definition of continence (66% for sling and 65% for
AUS) also confirmed noninferiority (difference –1.7 [95% CI
Patients screened (n = 840)
Eligible patients (n = 715)
Randomised (n = 380)
Responded at baseline (n = 183)
Received sling (n = 178)
Received sphincter (n = 2)
Ineligible patients (n = 125)
* Missed appointment (n = 17)
* Unresolved condition (n = 18)
* No previous prostate surgery (n = 2)
* USI not confirmed (n = 27)
* Previous USI surgery (n = 7)
* Inadequate dexterity (n = 1)
* No incontinence (n = 29)
* Operation cancelled (n = 2)
* Not suitable for surgery (n = 22)
* Unable to consent (n = 3)
* Unable to complete questionnaires (n = 4)
* Does not want surgery (n = 122)
Excluded (n = 335)
* Changed mind after consent (n = 5)
* Other reasons (n = 46)
* Urologist preference for AUS (n = 48)
* Urologist preference for sling (n = 11)
* Man preference for AUS (n = 85)
* Man preference for sling (n = 50)
* Does not want to be randomised (n = 9)
Artificial urinary sphincter (n = 190)
Responded at baseline ( n = 178)
Received sling ( n = 9)
Received sphincter ( n = 164)
6 mo6 mo
12 mo12 mo
* Reached (n = 190)
* Reached (n = 190)
* Withdrawn (n = 0)
* Withdrawn (n = 2)
* Died (n = 0)
* Died (n = 2)
* Responded (n = 117)
* Reached (n = 190)
* Withdrawn (n = 0)
* Died (n = 0)
* Responded (n = 125)
* Reached (n = 190)
* Withdrawn (n = 0)
* Died (n = 0)
* Responded (n = 157)
Note: Patients can be ineligible and excluded for more than one reason
* Responded (n = 161)
Male sling (n = 190)
Fig. 1 – Trial profile. AUS = artificial urinary sphincter; USI = urodynamic stress incontinence.
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frequency of leakage was similar between the groups;
however, the self-reported amount of leakage was higher in
the male sling group (odds ratio 1.64 [95% CI 1.02–2.65], p =
0.04; Table 2). A subgroup analysis of the primary outcome
is shown in the Supplementary material (Supplementary
Table 4 and Supplementary Fig. 2A and 2B). All the subgroup
analyses show a large amount of uncertainty around the
effect sizes, but suggest that the male sling is inferior to the
sphincter for men with greater incontinence at baseline
(pad weight >250 g); however, the difference does not
reach statistical significance. The subgroup analyses also
suggest that the male sling may perform better than the AUS
for men with pure SUI at baseline.
3.3. Secondary outcomes
In both groups, there was a reduction from baseline to
12 mo in the ICIQ-UI SF score [8], which measuresincontinence symptoms. The effect size shows inconti-
nence symptoms, at 12 mo, to be worse in the male sling
group with the CI excluding zero and therefore indicating
that this difference is significant (mean difference 1.4 [95%
CI 0.2–2.6], p = 0.02). Preoperative incontinence was
analysed by symptomatic type, SUI, and urgency urinary
incontinence (UUI), and by severity of incontinence, with
five grades from “never” to “all the time”. At baseline, 16%
of men had pure SUI, 61% had predominant SUI, 12% had
equal severity SUI and UUI, 4% had predominant UUI, and
7% did not enter their severity grades. At 12 mo, the men
with pure SUI had better dry rates (21% and 48%) on the
two outcome measures than those with SUI, plus any
element of UUI (13% and 32%). The odds ratios for the
original definition of incontinence is 0.42 (95% CI 0.20,
0.88; p = 0.02), and for the less strict definition of
incontinence it is 0.42 (95% CI 0.19, 0.93; p = 0.03). Both
of these show that men with pure SUI are less likely to be
incontinent at 12 mo.
Table 1 – Baseline characteristics
Male sling AUS
N = 190 N = 190
Age (yr) 68 (64, 71) 69 (63, 72)
ICIQ-UI SF 16 (14, 19); (N = 172) 17 (14, 19); (N = 166)
Score for effect on everyday life 8 (6, 10); (N = 178) 8 (7, 10); (N = 176)
24-h pad test result (g) 256 (89, 545); (N = 159) 267 (130, 554); (N = 159)
Pads used on an average day 3 (2, 4); (N = 180) 3 (2, 5); (N = 173)
EQ-5D 0.848 (0.760, 1.000); (N = 177) 0.850 (0.760, 1.000); (N = 172)
How often do you leak urine?
Two or three times a week 3 (1.6) 1 (0.5)
About once a day 3 (1.6) 2 (1.1)
Several times a day 115 (60.5) 104 (54.7)
All the time 54 (28.4) 59 (31.1)
Missing 15 (7.9) 24 (12.6)
How much urine do you usually leak?
A small amount 38 (20.0) 29 (15.3)
A moderate amount 76 (40.0) 84 (44.2)
A large amount 68 (35.8) 61 (32.1)
Missing 8 (4.2) 16 (8.4)
Do you wear pads or protection because of leaking urine?
No 5 (2.6) 4 (2.1)
Yes 175 (92.1) 171 (90.0)
Missing 10 (5.3) 15 (7.9)
Received radiotherapy for prostatic disease 38 (20.0) 39 (20.5)
Leaking urine before first prostate operation
No 174 (91.6%) 173 (91.1)
Yes 6 (3.2%) 10 (5.3)
Missing 10 (5.3%) 7 (3.7)
Reason for previous prostate surgery
Prostate cancer 178 (93.7) 180 (94.7)
Benign prostate obstruction 8 (4.2) 9 (4.7)
Both 4 (2.1) 1 (0.5)
Previous surgery or treatments
Radical prostatectomy 180 (94.7) 181 (95.3)
Channel TURP for obstructed prostate cancer 2 (1.1) 4 (2.1)
Transuretheral prostatectomy for benign prostatic obstruction 13 (6.8) 7 (3.7)
Retropubic prostatectomy for benign prostatic obstruction 1 (0.5) –
Injectable treatment for stress urinary incontinence 9 (4.7) 8 (4.2)
Physiotherapy for stress urinary incontinence 94 (49.5) 83 (43.7)
Drug treatment with duloxetine for urinary stress incontinence 23 (12.1) 21 (11.1)
Drug treatment for other urinary/bladder problem 40 (21.1) 35 (18.4)
Any neurological disease 2 (1.1) 7 (3.7)
AUS = artificial urinary sphincter; ICIQ-UI SF = International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form questionnaire;
TURP = transurethral resection of the prostate.
The summaries in this table are count and percentage for the categorical variables, and for continuous variables the summary is: median (lower quartile, upper
quartile); (number of observations).
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leaking urine interfere with your everyday life?” (where
zero indicates “not at all” and 10 “a great deal”), the
difference of 0.9 (95% CI 0.2–1.5, p = 0.01) shows that those
in the male sling arm experience significantly greater
interference in their everyday lives (Table 2, and Supple-
mentary Fig. 1A and 1B).
Postoperative pad use is similar in both the sling and the
AUS group. The effect size (incidence rate ratio) of
1.20 suggests a slightly higher use in the sling group, but
the CI of (0.95, 1.53) shows that the level of uncertainty
makes the difference not significant (Table 2, and Supple-
mentary Fig. 1C and 1D).
3.3.1. Satisfaction
Satisfaction (ICIQ-satisfaction [13]) with the outcome of
surgery was much greater for the AUS group: 104 (72.2%)were completely or fairly satisfied) in the male sling group
and 125 (90.6%) in the AUS group (difference –18.4% [–27.2,
–9.6], p < 0.001; Supplementary Table 1); 72.0% and 84.5%
of men in the sling and AUS groups, respectively, would
recommend their procedure to a friend (difference –12.5%
[–21.7, –3.2], p = 0.01; Supplementary Table 2); satisfaction
was positively associated with a greater decrease in self-
reported degree of urine loss (p < 0.001); and for men with
a preoperative 24-h pad weight of <250 g, 72% of the sling
and 88% of the AUS men were satisfied, and in men with a
pad weight of >250 g, satisfaction rates were 77% in the
sling and 95% in the AUS group. An odds ratio of 2.17 (95% CI
0.43, 11.02, p = 0.4; Fig. 2) shows that when the type of
incontinence (pure SUI, predominant SUI, SUI = UUI, and
predominant UUI) is analysed according to baseline 24-h
pad tests (<250 or >250 g) and satisfaction with surgery,
there is greater satisfaction in the AUS group than in the
Table 2 – Outcome data
Male sling AUS Difference (95% CI); p value Odds ratio (95% CI)
N = 154 N = 158
Incontinent a 134 (87.0) 133 (84.2) –3.6 (–11.6, 4.6); pNI = 0.003 0.75 (0.36, 1.54)
Incontinent—less strict b 102 (66.2) 103 (65.2) –1.7 (–10.1, 6.7); pNI = 0.001 0.92 (0.62, 1.35)
Per protocol N = 151 N = 145
Incontinent 131 (86.8) 123 (84.8) –2.7 (–10.9, 5.6); pNI = 0.002 0.80 (0.39, 1.63)
Incontinent (less strict) 99 (65.6) 95 (65.5) –1.2(–9.7, 7.3); pNI = 0.001 0.95 (0.64, 1.39)
N = 151 N = 154 Odds ratio (95% CI) c
How often do you leak urine?
Never 21 (13.9) 25 (16.2) 1.25 (0.89, 1.76); p = 0.2
Once a week or less 31 (20.5) 27 (17.5)
Two or three times a week 13 (8.6) 13 (8.4)
About once a day 12 (7.9) 20 (13.0)
Several times a day 59 (39.1) 60 (39.0)
All the time 15 (9.9) 9 (5.8)
N = 154 N = 158
How much urine do you usually leak?
None 20 (13.0) 26 (16.5) 1.64 (1.02, 2.65); p = 0.04
A small amount 91 (59.1) 103 (65.2)
A moderate amount 29 (18.8) 21 (13.3)
A large amount 14 (9.1) 8 (5.1)
Effect size (95% CI) d
ICIQ-UI SF 8.7 (6.1); (N = 151) 7.5 (5.3); (N = 153) 1.4 (0.2, 2.6); p = 0.02
Score for effect on everyday life 3.5 (3.4); (N = 155) 2.7 (2.9); (N = 157) 0.9 (0.2, 1.5); p = 0.01
EQ-5D 0.809 (0.260); (N = 151) 0.813 (0.274); (N = 158) –0.019 (–0.062, 0.024); p = 0.4
Wears pads or other protection 102/148 (68.9%) 102/150 (68.0%) 2.1 (–11.0, 15.2); p = 0.8
Pads used in an average day 1.6 (2.1); (N = 146) 1.3 (1.7); (N = 150) 1.25 (0.99, 1.58); p = 0.06
Pad weight (g) 30.0 (85.3); (N = 50) 73.7 (451.6); (N = 44)
AUS = artificial urinary sphincter; CI = confidence interval; ICIQ-UI SF = International Consultation on Incontinence Questionnaire-Urinary Incontinence Short
Form questionnaire.
Cells are n/N (%); the p value is from a test of noninferiority.
a The definition of incontinent is a participant who has indicated any frequency other than “never” or an amount greater than “none”.
b The less strict definition of incontinent is a participant who has indicated a frequency greater than “once a week or less” or an amount greater than “a small
amount”.
c The reference group is AUS.
d The effect sizes for ICIQ-UI SF score for effect on everyday life and EQ-5D are adjusted mean differences. For “wearing pads or other protection”, the effect size is
an adjusted risk difference, and for “pads used in an average day”, it is an incidence rate ratio adjusted for baseline pad quantity and previous radiotherapy, and
clustered by centre.
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ratio 0.41 [95% CI 0.24, 0.71], p < 0.001).
3.3.2. Surgery and AEs
Details of surgery received are shown in Figure 1. The mean
durations of the surgery and hospital stay were, respectively,
1.7 h and 1.6 d for the male sling and 2.1 h and 1.5 d for the
AUS group. In-patient AEs (expected and nonexpected) were
recorded during the men’s hospital stay (Table 3). There were
225 nonserious AEs in 154/180 (85.6%) men in the male sling
group compared with 189 in 147/173 (85.0%) men in the AUS
group. A post hoc analysis shows that significantly more men
in the male sling group (n = 49, 27.2%) had two or more AEs
than those in the AUS group (n = 28, 16.2%;
difference = 11.0%, 95% CI 2.5%, 19.5%; p = 0.01).
Serious adverse events (SAEs) were few, and experienced
by six men in the male sling group (recatheterisation
requiring or prolonging hospital stay [n = 3], mesh erosion
[n = 1], infection [urosepsis, n = 1], and development of
coffee ground vomit [n = 1]) and 11 men in the AUS group
(recatheterisation requiring or prolonging hospital stay
[n = 3], infection [n = 3], erosion of device [n = 2], haema-
toma [n = 1], bruising and inflammation [n = 1], urinaryretention/voiding difficulties [n = 1], pain [n = 1], transient
hypotension [n = 1], and thrombosis [n = 1], and three SAEs
in one man). Men who receive a sling are less likely to
experience an SAE, but there is a considerable level of
uncertainty around the estimate (incidence rate ratio
0.44 [0.16, 1.25], = 0.1).
The only difference in AEs was a greater number of
catheter problems in the male sling group: 45 men (25.0%)
in the male sling group versus 13 men (7.5%) in the AUS
group (difference 17.5% [10.0, 24.9], p  0.001).
3.3.3. Patient-reported AEs
AEs identified from the 12-mo questionnaire referred to the
12 mo from randomisation (Supplementary Table 3). There
were 51/157 (32.5%, male sling) and 36/161 (22.2%, AUS) AEs
reported, with higher numbers in the male sling group for
new bladder symptoms (7.6% in the male sling vs 1.2% in the
AUS group; difference 6.4% [1.9, 10.9], p = 0.01), infections
including urinary tract infections (12.1% in the male sling vs
6.8% in the AUS group; difference 4.6% [–1.5, 10.7], p = 0.1),
and surgical site pain (21.7% in the male sling vs 11.2% in the
AUS group; difference 10.5% [2.4, 18.6], p = 0.01). Device
problems (not working as well as hoped) were more
Fig. 2 – Forest plot of satisfaction with surgery. CI = confidence interval; SUI = stress urinary incontinence.
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group; difference –2.9% [–9.2, 3.4], p = 0.4).
3.3.4. Readmissions for additional surgery within 12 mo
There were 16 readmissions for further or additional UI
surgery, 13 in the male sling group and three in the AUS
group. A total of 13 male slings failed to improve the men’s
incontinence, 12 men in the male sling group had an AUS
implanted, and one man received a second sling—none of
these were removed. In the AUS group, three had revision
for mechanical failure (change of balloon reservoir, balloon
replacement, or repositioning; 5.5% [1.2, 9.7], p = 0.01;
Table 4).
Overall, 70 (20%) of the 353 randomised men who
received surgery had previous radiotherapy. In those
readmitted, 53% had had radiotherapy (7/14 from the male
sling group and 3/5 from the AUS group), while only 18%
(60/334) of those not readmitted received prior radiothera-
py, confirming that prior radiotherapy leads to worse
outcomes from both treatments (34.7% [11.8, 57.5], p =
0.0002).
4. Discussion
The primary outcome showed that AUS and male sling
surgeries were equally clinically effective at 12 mo, con-
firming noninferiority. However, MASTER found a much
higher prevalence of incontinence after PPI surgery than is
reported in the existing literature [14–17], with only 15% of
men in both groups saying that they never leaked. The
2018 American Urological Association guidelines [18] givethe “cure” rate for a male sling at 62%, but point out that the
definition of cure varies between 14 papers, as are the
definitions of “improved”: little evidence was found for the
AUS. There are several possible reasons for our finding of a
low cure rate. Firstly, our use of a very strict definition of “no
incontinence” using a PROM to determine the primary
outcome ensured stringent criteria for cure. Secondly, this
finding is perhaps not surprising, as present PPI surgical
techniques cannot be expected to fully recreate the
continence mechanisms that existed prior to radical
prostatectomy. Thirdly, the wide inclusion criteria applied
in MASTER resulted in our cohort exhibiting the full
spectrum of UI severity at study entry. Despite the large
proportion of men still having some degree of UI after
implantation of an AUS or a sling for PPI, incontinence is
much improved in most men. From clinical experience, we
know that men after PPI surgery are often satisfied with
their surgery even if not completely dry. With this in mind, a
satisfaction outcome measure was included in MASTER. As
discussed below, this instrument has allowed us to
understand how we can present the results of MASTER to
men with PPI who are contemplating surgery.
Both the primary and several secondary outcome
measures are dependent on PROMs. We felt that patients’
statements as to whether or not they were dry, and on other
aspects of their experience after surgery, should be the most
important sources of data for interventions that are
primarily designed to improve their quality of life. Not
only is MASTER the first high-quality RCT to examine
outcomes after surgical treatment of PPI by comparison of
the two most commonly used procedures, the AUS and the
Table 3 – Adverse events
Male sling AUS
Received operation 180/190(94.7) 173/190(91.1)
Serious adverse events a 6 13
Total number adverse events 225 189
N = 180 N = 173
Number of participants with any adverse events 152 (84.4) 147 (85.0)
Number of adverse events per participant
0 28 (15.6) 26 (15.0)
1 102 (56.7) 119 (68.8)
2 34 (18.9) 18 (10.4)
3 11 (6.1) 6 (3.5)
4 5 (2.8) 4 (2.3)
Type of adverse event
Postop catheter required 28 (15.6) 8 (4.6)
Catheter required for >24 h 20 (11.1) 6 (3.5)
Urinary tract infection 2 (1.2)
Pyrexia 1 (0.6) 3 (1.7)
Wound infection 3 (1.7) 1 (0.6)
Sepsis, septicaemia, or abscess 1 (0.6)
Retention requiring surgery 1 (0.6)
Bowel obstruction 1 (0.6)
Constipation 1 (0.6) 3 (1.7)
New urinary tract symptoms 2 (1.1)
Tape or male sling complications 1 (0.6)
Device exposure/extrusion requiring no treatment 1 (0.6) b
Acute or chronic pain 1 (0.6) 1 (0.6)
Oral pain relief given 139 (77.2) 137 (79.2)
Parenteral pain relief given 13 (7.2) 12 (6.9)
Antibiotic treatment for postop infection 6 (3.3) 10 (5.8)












Received operation 144/152 (94.7%) 36/38 (94.7%) 139/151 (92.1%) 34/39 (87.2%)
Serious adverse events 3 3 9 4
Total number of adverse events 187 38 154 35
N = 152 N = 38 N = 151 N = 39
Number of participants with any adverse events 124 (86.1%) 28 (77.8%) 121 (87.1%) 26 (76.5%)
Number of complications per participant
0 20 (13.9%) 8 (22.2%) 18 (12.9%) 8 (23.5%)
1 82 (56.9%) 20 (55.6%) 98 (70.5%) 21 (61.8%)
2 28 (19.4%) 6 (16.7%) 15 (10.8%) 3 (8.8%)
3 9 (6.3%) 2 (5.6%) 6 (4.3%)
4 5 (3.5%) 2 (1.4%) 2 (5.9%)
Type of adverse event
Postop catheter required 24 (16.7%) 4 (11.1%) 7 (5.0%) 1 (2.9%)
Catheter required for >24 h 14 (9.7%) 6 (16.7%) 6 (4.3%)
Urinary tract infection 1 (0.7%) 1 (2.9%)
Pyrexia 1 (0.7%) 2 (1.4%) 1 (2.9%)
Wound infection 3 (2.1%) 1 (0.7%)
Sepsis, septicaemia, or abscess 1 (0.7%)
Retention requiring surgery 1 (0.7%)
Bowel obstruction 1 (0.7%)
Constipation 1 (0.7%) 2 (1.4%) 1 (2.9%)
New urinary tract symptoms 2 (1.4%)
Tape or sling complications 1 (0.7%)
Device exposure/extrusion requiring no treatment 1 (0.7%)
Acute or chronic pain 1 (0.7%) 1 (2.9%)
Oral pain relief given 114 (79.2%) 25 (69.4%) 112 (80.6%) 25 (73.5%)
Parenteral pain relief given 12 (8.3%) 1 (2.8%) 8 (5.8%) 4 (11.8%)
Antibiotic treatment for postop infection 5 (3.5%) 1 (2.8%) 10 (7.2%)
Other adverse events 3 (2.1%) 1 (2.8%) 2 (1.4%)
AUS = artificial urinary sphincter; SAE = serious adverse event.
a SAEs were as follows: male sling group—recatheterisation requiring or prolonging hospital stay (n = 3), mesh erosion (n = 1), infection (urosepsis, n = 1), and
development of coffee ground vomit (n = 1); AUS group—recatheterisation requiring or prolonging hospital stay (n = 3), infection (n = 3), erosion of device (n
= 2), haematoma (n = 1), bruising and inflammation (n = 1), anaesthetic complication (n = 1), urinary retention/voiding difficulties (n = 1), pain (n = 1), transient
hypotension (n = 1), and thrombosis (n = 1), and three SAEs in one man.
b Herniated AUS reservoir through abdominal hernia (device still present, not causing any problems).
c Other adverse events: the four events in the male sling group are as follows: extended hospital stay due to few minutes of loss of transient consciousness, left
leg pain, and difficulty bearing weight; large postvoid residuals; retention requiring recatheterisation, and rash in the right groin; the two events in the AUS group
are urinary retention after discharge and intraoperative ventricular tachycardia.
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Table 4 – Readmissions within 12 mo
Male slingArtificial urinary sphincter
N = 180 N = 173
Further USI surgery 13 (7.2%) 2 (1.2%)
Additional surgery 1 (0.6%)
Participants with any readmission13 (7.2%) 3 (1.8%)
Pain due to further surgery 1 (0.6%)
USI = urodynamic stress incontinence.
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subject area and the first to use a full range of validated
PROMs to evaluate outcomes, making it generalisable across
current practice.
Some might regard pad testing or UDS as more objective
than PROMs, and therefore a better choice when selecting a
primary outcome. However, pad testing has a complex
literature, with some recommending that a 1-h pad test
should include a standardised exercise regime; these issues
make pad testing problematic for the primary outcome. We
felt that the 24-h test was superior and a useful metric at
baseline, but we also knew from experience that it would
probably be hard to get a lot of men to repeat their 24-h pad
tests at 12 mo if they were more or less dry, and the research
nurses confirmed this to be so. Similarly, we did not feel that
UDS should be an outcome measure. As UDS is the standard
of care in the UK prior to PPI surgery, we felt that it should be
included in MASTER. It was our view that, if SUI was not
demonstrated at UDS, then other causes, such as detrusor
overactivity, might be the cause of the man’s symptoms and
he would not respond to PPI surgery. In MASTER, we wished
to be sure that all men had the condition that we sought to
evaluate, namely, SUI. We intend to analyse and publish
separately any symptom associations with preoperative
urodynamic features, such as detrusor overactivity, which
might have impacted outcome.
By using a PROM, it was possible to analyse outcomes by
incontinence subgroups and severity of incontinence, and
this indicated that men with pure SUI had better dry rates
(21% and 48%, respectively), on the two outcome measures,
than those presenting with SUI plus any element of UUI (13%
and 32%, respectively). These data are supported by the
satisfaction data related to baseline pad weight and
incontinence group, which favours AUS over male slings
(Fig. 2). This information will help in a more complete
discussion prior to PPI surgery.
Whist the primary outcome showed that a male sling is
not inferior to an AUS, and UI (using the validated ICIQ-UI SF
[8]) was greatly reduced after surgery in both groups,
differences were seen in the secondary outcome measures,
almost all of which show greater improvement for the AUS
than for the male sling group. The additional quality of life
question showed that improvement favoured the AUS, the
self-reported amount of urine leakage postoperatively was
higher in the male sling group, and the mean pad usage
decreased more in the AUS group. There was also higher
overall satisfaction with an AUS, despite the majority of men
still reporting some urine leakage: this included 85% versus72% in the sling group, who were prepared to recommend
the AUS operation to a friend. Men in both groups were
generally satisfied with their improvement and accepted
the fact that, although not cured, they were sufficiently
improved to be satisfied.
There were fewer AEs and lower rates of further surgery
in the men having an AUS than in men having a male sling,
although there were more SAEs for the AUS group. A total of
225 AEs were reported in the male sling group compared
with 189 in the AUS group, with many more catheter-
related AEs in the male sling group. It is likely that this was
because some men were not routinely catheterised after
male sling surgery and required catheterisation within 24 h
after surgery due to inability to void adequately. At 12 mo
after surgery, significantly more repeat continence surger-
ies were necessary in the male sling group than in the AUS
group, largely due to the failure of slings to control leakage
in men. However, it is likely that sling failures will occur
early, and it may be that the 5-yr follow-up, which we
intend to perform, will show later failures in the AUS men.
Of all men, from both groups, who required additional
surgery, radiotherapy was over-represented, with 53% of
these men having had radiotherapy prior to radical
prostatectomy. More men in the male sling group reported
problems with infections, new bladder symptoms, and pain
at the site of surgery or elsewhere. Although we do not feel
that chronic pain is a major problem for men after PPI
surgery, because of the controversies in women over mesh
used for stress incontinence and pelvic organ prolapse
surgery, we are planning an early, more detailed review of
pain in our patient group. On the contrary, men in the AUS
group had more problems with the device, as might be
expected for a device that requires patient activation, and
few SAEs were experienced by six men in the male sling
group compared with 13 SAEs experienced by 11 men in the
AUS group—neither of these outcomes reached statistical
difference.
The often-stated potential advantages of a male sling
compared with an AUS are reduction in length of hospital
stay, lower cost, fewer complications, and fewer reoperation
rates. However, none of these were confirmed in MASTER.
The length of stay for sling surgery was not reduced, and this
may have been because most men were catheterised, as
some surgeons may have felt it wise to catheterise all men
after sling surgery for a minimum of 24 h. However, there is
a theoretical “trade-off” between fewer urinary tract
infections if the men do not have a postop catheter and a
faster discharge home, but with the need for a percentage
requiring recatheterisation after surgery, as was seen in the
sling group. In addition, more male sling patients required
repeat continence surgery. The suggested potential of male
slings to reduce the number of complications and reopera-
tion rates of the AUS was not apparent at 12 mo, and longer
follow-up will be required to assess whether there are
significant differences in this respect.
As device-related complications do not always occur in
the first 12 mo, longer-term data acquisition has been
advised for all surgical devices, as highlighted recently by
the Royal College of Surgeons of England [19]; hence, we
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cohort. The planned 24-mo follow-up will be important for
its health-economic analyses (HEAs), which will add cost-
effectiveness data to longer-term clinical effectiveness to
guide overall decision-making on service design and
provision. The HEAs will be comprehensive and include,
for example, the use of medications and reoperations and
other relevant admissions to hospital.
Prior to MASTER, the widespread view was that a trial
comparing these interventions would not be possible due to
a lack of equipoise from both surgeons and patients. Despite
this, we recruited above the minimum target sample size.
We think that the success in recruitment was in part due to
the surgeons from the sites meeting early in the planning
stage. We tackled the issue of our equipoise and challenged
each other’s views, for example, that male slings were for
mild and AUS for severe incontinence, and whether men
who had had radiotherapy should be excluded. We agreed
that the evidence on these issues was usually of level 4 and
considered that the literature did not contain sufficient
evidence to be able to write the inclusion and exclusion
criteria for many of the views we had held. Hence, we felt
that the RCT should be pragmatic and not exclude
individuals unless there were clear safety issues or
convincing data on poor outcome. We have used a multi-
centre, pragmatic trial design, with wide inclusion criteria,
to ensure that both procedures were tested in a manner
aligned with present clinical practice, making the results
generalisable. We were able to test many of the hypotheses
that can be found in literature dominated by case series,
which can provide only lower-level quality of evidence
[4]. Hence, there is now good-quality evidence from the
PROMS to show that even men with greater leakage can be
offered the sling procedure, after full discussion of the
findings of MASTER, as most men were satisfied with a sling.
When we tested for a difference between the <250 g and
>250 g leakage levels, on the baseline 24-h pad tests, the
effect size was 0.62 (0.16, 2.36; p = 0.4). However, in a
requested post hoc analysis of the question “leak urine
when sleeping?”, there was a statistical association
between increased leakage during sleep and higher 24-h
pad weights, for example, for leakage “occasionally”, the
mean pad weight was 327 ml, whereas for “most of the
time”, it was 615 ml. Although men who had developed UI
after TURP for benign prostatic obstruction, prior to their
PPI surgery, were included, there were only eight of 190 in
the male sling group and nine of 190 in the AUS group, and
these numbers were too small to offer a useful analysis.
A limitation of this study is that we were unable to
compare the severity of the MASTER men’s incontinence
with that of men in the case series reports, because the data
from previous non-RCT studies do not contain adequate
information for comparison. However, men in MASTER
were more incontinent than the men included in the only
other reported RCT [3], which contained a significant
number of men described as “minimally incontinent”.
The wide range of PROMs allowed us to look at the trial
results from a number of other perspectives. Additionally, a
recent study by Machioka et al [15] supports our use of thevalidated ICIQ-UI SF as an effective tool in evaluating UI after
radical prostatectomy. The use of PROMs for the primary and
secondary outcomes at baseline and 12 mo, together with
the large number of men included, means that results from
MASTER can be regarded as authoritative. MASTER provides
a significant advance to the literature, and is the highest-
quality evidence available to date to guide patients and
clinicians when considering surgical intervention for PPI.
In summary, the results of MASTER indicate that men
should be counselled that both AUS and male slings are
effective in significantly reducing urinary leakage. In the
majority of men, both procedures improve quality of life,
and satisfaction rates are high. However, “true cure”, which
is the absence of any leakage under any circumstances,
cannot be expected in most men. A man debating on
whether to have a male sling or an AUS is likely to decide on
the basis of the benefits and risks of the two procedures.
MASTER shows that the advantage of the simplicity of use of
a male sling (in that it does not require the man to
manipulate his device in order to void) must be balanced
against some increased risks. The male sling group had
higher incidences of postoperative recatheterisation, and at
12 mo, the male sling patients reported larger leakage
quantities and higher use of pads, with less improvements
in quality of life and satisfaction. The male sling group also
has higher incidences of infections, new bladder symptoms,
and surgical site pain. However, patients report a higher
incidence of device problems (fault with balloon reservoir
or requiring repositioning) with an AUS. Finally, patients
should be told that in the male sling group, within 12 mo,
there is a three-fold higher risk of needing a repeat
continence operation and an increased risk of pain. All
statistical secondary and post hoc analyses were in favour of
the AUS. As to why there should be advantages of the AUS
over the sling, we can speculate that it is possible that the
circumferential positive pressure of the AUS works some-
what better than the unidirectional elevation offered by the
sling. In addition, we are able to state that previous
radiotherapy increases the risk of reoperation in any
operation for PPI.
There is little evidence to support the view that a male sling
should be used for mild/moderate incontinence and an AUS for
severe incontinence. Both devices perform well irrespective of
whether or not the baseline 24-h pad testing showed leakage
above or below 250 g (Supplementary Table 4).
These initial results allow a better-informed consent
process when a man discusses PPI procedures with his
surgeon.
5. Conclusions
MASTER has provided the highest evidence (level 1) at
12 mo that both the AUS and the male sling procedure lead
to improvement in most men with PPI, but do not
completely “cure” the majority. The trial outcomes can be
used when advising men on whether to have PPI surgery
and whether they should consider the AUS or male sling
procedure or neither. The results will allow detailed
discussion regarding the benefits and risks of both
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balanced with the need to manually operate the AUS, while
the male sling group has higher complication rates. These
results have provided, for the first time, information that
allows fully informed consent. The evidence from MASTER
will also inform clinical practice through evidence-based
guidelines.
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